1.
Asian Pac J Allergy Immunol
;
1987 Jun; 5(1): 13-6
Artículo
en Inglés
| IMSEAR
| ID: sea-36525
RESUMEN
Recombinant interleukin-2 (RIL-2) and lymphokine-activated killer (LAK) cells were administered to 2 boys with the end-stage of primary hepatocellular carcinoma (HCC); the efficacy and toxicity were evaluated. Immunologically, the natural killer and LAK activities were enhanced. Clinically, the side effects were similar to those reported for adults but milder. This kind of treatment may be considered for children with the early stages of hepatocellular carcinoma.